{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-24-000023","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.306703+00:00","generated_at":"2026-06-01T05:00:58.438763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen FY2024 net loss narrows to $29.4M; fasedienol Phase 3 program on track","bullets":["Net loss of $29.4M for FY2024, down from $59.2M in FY2023; cash and equivalents $119.2M as of March 31, 2024.","R&D expenses decreased to $20.0M from $44.4M, primarily due to timing of fasedienol Phase 3 trials.","PALISADE-3 Phase 3 trial for fasedienol in SAD initiated; PALISADE-4 expected in 2H 2024; positive PALISADE-2 results previously.","Appointed Cindy Anderson as CFO; entered exclusive negotiation with Fuji Pharma to develop PH80 in Japan for menopausal hot flashes.","Completed underwritten public offering to fund pipeline milestones; itruvone Phase 2B planning underway for MDD."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-24-000023","json":"https://secwatch.observer/filing/0001411685-24-000023.json","markdown":"https://secwatch.observer/filing/0001411685-24-000023.md","text":"https://secwatch.observer/filing/0001411685-24-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168524000023/0001411685-24-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168524000023/vtgn-20240611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:00:58.438763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}